ATHE
Alterity Therapeutics Limited
NASDAQ · Healthcare · Biotechnology · AU
$4.54
+0.44%Income statement
| Metric | TTM | 2026 | 2025 | 2024 | 2023 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 5.4M | — | 5.4M | 4.0M | 3.9M |
| Cost of Revenue | 242.8K | 113.0K | 127.5K | 214.3K | 285.1K |
| Gross Profit | 5.2M | (113.0K) | 5.3M | 3.8M | 3.6M |
| Operating Expenses | |||||
| R&D Expense | 32.0M | 17.2M | 14.4M | 18.6M | 13.2M |
| SG&A Expense | 16.1M | 10.4M | 5.5M | 4.8M | 5.0M |
| General & Admin Expense | 5.5M | — | 5.5M | 4.8M | 5.0M |
| Selling & Marketing Expense | — | — | — | (9.7K) | 51.5K |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 48.2M | 27.7M | 19.9M | 23.4M | 18.2M |
| Cost and Expenses | 48.4M | 27.8M | 20.0M | 23.6M | 18.5M |
| Operating Income (EBIT) | (43.0M) | (27.8M) | (14.6M) | (19.6M) | (14.6M) |
| Non-Operating | |||||
| Interest Income | 2.2M | 1.7M | 446.3K | 268.4K | 16.4K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 2.2M | 1.7M | 446.3K | 268.4K | 16.4K |
| Other Non-Op Income/Expense | 2.4M | 1.5M | 2.5M | 524.3K | 904.7K |
| Non-Operating Income (excl Interest) | 87.3K | — | 87.3K | 5.2K | 29.4K |
| EBT (Pre-Tax Income) | (40.6M) | (26.3M) | (12.1M) | (19.1M) | (13.7M) |
| Income Tax Expense | (5.0M) | (3.4M) | 68.1K | 46.1K | 104.5K |
| Bottom Line | |||||
| Net Income | (35.6M) | (22.9M) | (12.1M) | (19.1M) | (13.8M) |
| Earnings from Cont. Ops | (35.6M) | (22.9M) | (12.1M) | (19.1M) | (13.8M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (35.6M) | (22.9M) | (12.1M) | (19.1M) | (13.8M) |
| Per Share | |||||
| Basic EPS | ($2.58) | ($1.32) | ($1.14) | ($3.12) | ($3.42) |
| Diluted EPS | ($2.58) | ($1.32) | ($1.14) | ($3.12) | ($3.42) |
| Revenue Per Share | $0.30 | $0.00 | $0.51 | $0.66 | $0.97 |
| Shares | |||||
| Basic Shares Outstanding | 18.1M | 17.5M | 10.7M | 6.1M | 4.0M |
| Diluted Shares Outstanding | 18.1M | 17.5M | 10.7M | 6.1M | 4.0M |
| Profitability Metrics | |||||
| EBITDA | (42.9M) | (27.7M) | (14.6M) | (19.6M) | (14.6M) |
| D&A | 143.6K | 113.0K | 28.3K | 35.3K | 37.9K |
| EBIT | (43.1M) | (27.8M) | (14.7M) | (19.6M) | (14.6M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026